/ / / Tab 3

Review Article

The Efficacy of Bisphosphonates in Preventing Aromatase Inhibitor Induced Bone Loss for Postmenopausal Women with Early Breast Cancer: A Systematic Review and Meta-Analysis

Table 3

Patient characteristics of included zoledronic acid trials.


Characteristic	Immediate group			Delayed group
Characteristic	Z FAST	ZO FAST	E-ZO FAST	Z FAST	ZO FAST	E-ZO FAST

Age, years
Median	60	57	58	60	58	58
Range	35–83	36–87	40–81	41–89	37–81	44–78
Race
White	280	—	226	269	—	242
Asian	—	89	21	—	93	19
Black	9	—	—	14	—	—
Caucasian	—	416	—	—	409	—
Other	12	27	5	18	31	9
Baseline score
score > −1	217	370	163	216	367	180
score ≤ −1 to ≥ −2	84	162	89	85	166	90
Postmenopausal status
Postmenopausal	281	445	210	284	443	228
Recently postmenopausal	—	87	42	—	90	42
Bone mineral density
Lumbar spine
Mean	1.110	1.08		1.106	1.08
SD	0.1652	0.16		0.1663	0.16
Median	1.088	1.07	—	1.082	1.06	—
Range	0.818–1.649	0.79–1.67		0.807–1.692	0.71–1.77
Total hip
Mean	0.958	0.96		0.955	0.96
SD	0.1259	0.13	—	0.1322	0.13	—
Median	0.954	0.94		0.943	0.94
Range	0.676–1.310	0.62–1.43		0.700–1.475	0.62–1.55